Lyell Immunopharma (LYEL) Operating Expenses (2020 - 2026)

Lyell Immunopharma (LYEL) has 7 years of Operating Expenses data on file, last reported at $44.3 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses fell 22.85% year-over-year to $44.3 million; the trailing twelve-month figure through Mar 2026 stood at $256.3 million (down 28.92% YoY), and the FY2025 full-year result was $269.4 million, down 24.91% from the prior year.
• Operating Expenses slipped to $44.3 million in Q1 2026, from $127.6 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $201.2 million in Q4 2024 to a low of $37.3 million in Q3 2025.
• A 5-year average of $70.1 million and a median of $59.5 million in 2023 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses jumped 237.96% in 2024 and sank 36.54% in 2025, its largest moves.
• Tracing LYEL's Operating Expenses over 5 years: stood at $63.2 million in 2022, then declined by 5.78% to $59.5 million in 2023, then jumped by 237.96% to $201.2 million in 2024, then slumped by 36.54% to $127.6 million in 2025, then sank by 65.32% to $44.3 million in 2026.
• Business Quant data shows LYEL's Operating Expenses at $44.3 million in Q1 2026, $127.6 million in Q4 2025, and $37.3 million in Q3 2025.